Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics CFTR Prior Auth Coverage | Open…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    CFTR Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, renewal, and quantity-limit review for CFTR modulator drugs for Boeing commercial members. It applies to providers requesting Alyftrek, Kalydeco, Orkambi, Symdeko, or Trikafta.

    Policy Summary
    PayerPrime Therapeutics
    PolicyCFTR Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Alyftrek, Kalydeco, Orkambi, Symdeko, or Trikafta with applicable FDA-labeled indication and age support, specialist involvement or consultation, and required clinical documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5CFTR modulator brands covered by the program
    12 monthsInitial and renewal approval duration
    84 tabletsSpecified Alyftrek quantity limit
    30 daysSpecified Orkambi supply quantity

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    28 daysSpecified Symdeko and Trikafta supply quantity

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • ONE of the following

      • ALL of the following

        • The patient has a diagnosis of cystic fibrosis.
        • The patient has CFTR gene mutation(s), confirmed by genetic testing, according to the FDA label for the requested agent.

          Medical records required.

        • If the requested agent is Kalydeco, the patient does NOT have an F508del mutation on BOTH alleles of the CFTR gene (not homozygous).
      • The patient has another FDA-labeled indication for the requested agent and route of administration.
    • ONE of the following, if the patient has an FDA-labeled indication

      • The patient's age is within FDA labeling for the requested indication for the requested agent.
      • There is support for using the requested agent for the patient's age for the requested indication.
    • The patient will NOT be using the requested agent in combination with another CFTR modulator agent (e.g., Alyftrek, Kalydeco, Orkambi, Symdeko, Trikafta) for the requested indication.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Continuation Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent will require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • The patient will NOT be using the requested agent in combination with another CFTR modulator agent (e.g., Alyftrek, Kalydeco, Orkambi, Symdeko, Trikafta) for the requested indication.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.

    Quantity-Limit Criteria

    Quantity-limit exceptions are covered when ALL applicable criteria are met:

    ONE of the following

    • The requested quantity (dose) does NOT exceed the program quantity limit.
    • The requested quantity (dose) exceeds the program quantity limit AND ONE of the following

      • BOTH of the following

        • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.
      • BOTH of the following

    Coverage is not provided when the requested agent is used concurrently with another CFTR modulator agent (e.g., Alyftrek, Kalydeco, Orkambi, Symdeko, or Trikafta) for the requested indication.

    Provider Actions and Decision Risks

    Prior Authorization

    Initial Prior Authorization Required

    Obtain prior authorization before initiating the requested agent. Initial approval requires the applicable clinical criteria, documentation, specialist involvement, and confirmation that the agent will not be used with another CFTR modulator for the requested indication.

    • For cystic fibrosis, confirm the diagnosis and a CFTR mutation supported by genetic testing and consistent with the FDA label for the requested agent.
    • For Kalydeco, document that the patient is not homozygous for the F508del mutation (does not have F508del on both CFTR alleles).
    • For another FDA-labeled indication, confirm the requested agent and route are labeled for that indication and that the patient's age is within labeling or supported for use at that age.
    • Confirm the prescriber is a specialist in the patient's diagnosis area (for example, cystic fibrosis or pulmonology), or has consulted with such a specialist.
    • Confirm the patient has no FDA-labeled contraindication to the requested agent.
    • Initial approval length: 12 months. If a quantity limit applies, submit the applicable quantity-limit documentation.
    Prior Authorization

    Clinical Background

    CFTR modulators are targeted therapies directed at the cystic fibrosis transmembrane conductance regulator pathway. Coverage may apply to cystic fibrosis when the patient has a CFTR mutation or mutation combination confirmed by genetic testing according to the FDA label for the requested agent, or to another FDA-labeled indication for the requested agent and route of administration.

    Eligibility is agent-specific and depends on the applicable FDA labeling, including the patient's CFTR variant profile and age. For an FDA-labeled indication, the patient's age must be within the labeled range or there must be support for use at the patient's age. The program includes Alyftrek, Kalydeco, Orkambi, Symdeko, and Trikafta.

    Key Definitions

    CFTR modulator agent
    DefinitionA treatment directed at the cystic fibrosis transmembrane conductance regulator pathway.
    Included agentsAlyftrek, Kalydeco, Orkambi, Symdeko, and Trikafta.
    UseCFTR modulator agents are evaluated under the policy for applicable FDA-labeled indications.
    FDA-labeled CFTR mutation
    Mutation or combinationA CFTR mutation or mutation combination associated with the requested agent.
    ConfirmationThe mutation or combination must be confirmed by genetic testing.
    FDA recognition

    Initial Therapy Criteria

    CFTR Modulator Initial Authorization

    Initial therapy is approved when ALL applicable criteria are met.

    Initial therapy

    • Covered indication

      • Cystic fibrosis pathway: The patient has a diagnosis of cystic fibrosis; CFTR mutation(s) are confirmed by genetic testing according to the FDA label for the requested agent; and, if the requested agent is Kalydeco, the patient does not have F508del mutations on both CFTR alleles.

        Medical records are required for genetic confirmation.

      • Other FDA-labeled indication: The patient has another FDA-labeled indication for the requested agent and route of administration.
    • Age requirement:

    Continuation Therapy Criteria

    CFTR Modulator Renewal

    Continuation therapy is approved when ALL of the following are met.

    Continuation therapy: The patient was previously approved for the requested agent through the plan's prior authorization process; has had clinical benefit; will not use the requested agent with another CFTR modulator for the requested indication; the prescriber is a specialist or has consulted with a specialist; and the patient has no FDA-labeled contraindication.

    Approval length is 12 months. Patients not previously approved require initial evaluation review.

    Product Quantity Limits

    Alyftrek 4-20-50 mg tablets
    Agent and strengthAlyftrek 4-20-50 mg tablets.
    Dosage formTablets.
    Quantity limit84 tablets per day supply period.
    Orkambi granules packets and tablets
    Granule packetsOrkambi 75-94 mg, 100-125 mg, and 150-188 mg granule packets.
    TabletsOrkambi 100-125 mg and 200-125 mg tablets.
    Supply quantity30 days.
    Policy Summary
    PayerPrime Therapeutics
    PolicyCFTR Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Alyftrek, Kalydeco, Orkambi, Symdeko, or Trikafta with applicable FDA-labeled indication and age support, specialist involvement or consultation, and required clinical documentation.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Decision RisksClinical BackgroundKey DefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaProduct Quantity Limits
    The patient does NOT have any FDA-labeled contraindications to the requested agent.
    The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication.
  1. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit.
  2. BOTH of the following

    • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
    • There is support for therapy with a higher dose for the requested indication.
  3. Renewal Prior Authorization

    Renewal requests require evidence that the requested agent was previously approved through the plan's prior authorization process and that continued therapy remains appropriate. Patients without prior plan approval require initial evaluation review.

    • Document prior approval for the requested agent through the plan's prior authorization process.
    • Document clinical benefit from the requested agent.
    • Confirm the requested agent will not be used in combination with another CFTR modulator for the requested indication, including Alyftrek, Kalydeco, Orkambi, Symdeko, or Trikafta.
    • Confirm the prescriber is a specialist in the patient's diagnosis area, or has consulted with a specialist.
    • Confirm the patient has no FDA-labeled contraindication to the requested agent.
    • Renewal approval length: 12 months. If a quantity limit applies, submit the applicable quantity-limit documentation.
    Documentation Required

    Clinical Records and Genetic Testing

    For cystic fibrosis requests, submit clinical records confirming the diagnosis and genetic testing results that identify a CFTR mutation supporting use of the requested agent under its FDA label.

    • Medical records confirming cystic fibrosis diagnosis are required.
    • Genetic testing must confirm the applicable CFTR mutation(s) according to the FDA label for the requested agent.
    • For Kalydeco, document that F508del is not present on both CFTR alleles (the patient is not F508del homozygous).
    Documentation Required

    Renewal Documentation

    Renewal documentation must establish continued eligibility for the requested agent. Include the prior plan approval, evidence of clinical benefit, specialist involvement or consultation, and confirmation that no contraindication or prohibited combination applies.

    • Provide the prior authorization approval history for the requested agent; requests without prior plan approval require initial review.
    • Document clinical benefit with continued treatment.
    • Identify the specialist prescriber or document consultation with a specialist in the patient's diagnosis area.
    • Confirm no concurrent use with another CFTR modulator for the requested indication.
    • Confirm no FDA-labeled contraindication to the requested agent.
    Documentation Required

    Quantity-Limit Exception Documentation

    When the requested dose or quantity exceeds the program limit, submit documentation supporting the higher quantity and the applicable dosing rationale. Approval requires either a quantity within the limit or one of the specified exceptions.

    • If the quantity does not exceed the program limit, document the requested dose and quantity.
    • If the quantity exceeds the limit and there is no maximum FDA-labeled dose for the indication, provide support for therapy with the higher dose.
    • If the quantity is within the maximum FDA-labeled dose, explain why the dose cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • If the quantity exceeds the maximum FDA-labeled dose, provide support for therapy with the higher dose.
    • Quantity-limit exception approval length: 12 months.
    Denial Risk

    Initial Authorization Criteria Not Met

    An initial request is at risk for denial when the initial clinical criteria are not met or required documentation is absent. Do not submit the request as approvable without resolving the applicable deficiency.

    • The patient does not have cystic fibrosis with a CFTR mutation confirmed by genetic testing according to the FDA label, and no other FDA-labeled indication for the requested agent and route is established.
    • For a non-cystic-fibrosis FDA-labeled indication, the patient's age is outside labeling and no support is provided for use at that age.
    • The patient will use the requested agent in combination with another CFTR modulator for the requested indication.
    • The prescriber is neither an appropriate specialist nor supported by documented specialist consultation.
    • The patient has an FDA-labeled contraindication to the requested agent.
    • For Kalydeco, the patient has F508del mutations on both CFTR alleles.
    • Required medical records, genetic testing, or other clinical support are not submitted.
    Denial Risk

    Renewal Criteria Not Met

    A renewal request is at risk for denial when continued-therapy requirements are not demonstrated. Patients not previously approved through the plan's prior authorization process must undergo initial evaluation review rather than renewal review.

    • The requested agent was not previously approved through the plan's prior authorization process.
    • Clinical benefit with the requested agent is not demonstrated.
    • The requested agent will be used with another CFTR modulator for the requested indication.
    • The prescriber is neither a specialist in the diagnosis area nor supported by specialist consultation.
    • The patient has an FDA-labeled contraindication to the requested agent.
    • Required renewal documentation is missing or insufficient.
    Denial Risk

    Quantity-Limit Exception Unsupported

    A quantity-limit exception is at risk for denial when the requested quantity exceeds the program limit without support for the applicable dosing exception. The request must show that the higher quantity is clinically supported and cannot be addressed through an allowed lower quantity or higher strength, when applicable.

    • The requested quantity exceeds the program limit and there is no support for therapy with a higher dose when the agent has no maximum FDA-labeled dose for the indication.
    • The requested quantity is within the maximum FDA-labeled dose, but no explanation shows why the dose cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • The requested quantity exceeds the maximum FDA-labeled dose and no support is provided for therapy with the higher dose.
    • The submitted dosing rationale does not establish medical necessity for the higher quantity.
    The confirmed mutation or combination must be recognized in the FDA label for the requested agent.
    For an FDA-labeled indication, the patient's age is within FDA labeling, or there is support for use in the patient's age for the requested indication.
  4. Additional requirements: The requested agent will not be used with another CFTR modulator for the requested indication; the prescriber is a specialist or has consulted with a specialist in the patient's diagnosis; and the patient has no FDA-labeled contraindication to the requested agent.

    Examples of CFTR modulators include Alyftrek, Kalydeco, Orkambi, Symdeko, and Trikafta.

  5. Symdeko strengths
    Higher strengthSymdeko 100-150 mg/ivacaftor 150 mg.
    Lower strengthSymdeko 50-75 mg/ivacaftor 75 mg.
    Supply quantity28 days.
    Trikafta strengths
    100-50-75 mg strengthTrikafta 100-50-75 mg/ivacaftor 75 mg.
    50-25-37.5 mg strengthTrikafta 50-25-37.5 mg/ivacaftor 75 mg.
    100-50-75 mg with ivacaftor 150 mgTrikafta 100-50-75 mg/ivacaftor 150 mg.
    Supply quantity28 days.